Published in Biochem J on February 01, 2003
TGF-beta-activated Smad3 represses MEF2-dependent transcription in myogenic differentiation. EMBO J (2004) 1.42
Structure of p300 bound to MEF2 on DNA reveals a mechanism of enhanceosome assembly. Nucleic Acids Res (2011) 1.06
Structure of the MADS-box/MEF2 domain of MEF2A bound to DNA and its implication for myocardin recruitment. J Mol Biol (2010) 0.97
Differentiation-dependent lysine 4 acetylation enhances MEF2C binding to DNA in skeletal muscle cells. Nucleic Acids Res (2007) 0.93
Targeting pioneering factor and hormone receptor cooperative pathways to suppress tumor progression. Cancer Res (2012) 0.85
Nuclear hormone receptor functions in keratinocyte and melanocyte homeostasis, epidermal carcinogenesis and melanomagenesis. FEBS Lett (2013) 0.78
Role of CBP/P300 in nuclear receptor signalling. Nature (1996) 7.36
Correlation of terminal cell cycle arrest of skeletal muscle with induction of p21 by MyoD. Science (1995) 7.25
Cooperative activation of muscle gene expression by MEF2 and myogenic bHLH proteins. Cell (1995) 6.24
Muscle-specific expression of the cardiac alpha-actin gene requires MyoD1, CArG-box binding factor, and Sp1. Genes Dev (1990) 3.62
Molecular mechanisms of myogenic coactivation by p300: direct interaction with the activation domain of MyoD and with the MADS box of MEF2C. Mol Cell Biol (1997) 3.62
A viral mechanism for inhibition of p300 and PCAF acetyltransferase activity. Cell (1999) 3.36
MyoD-induced expression of p21 inhibits cyclin-dependent kinase activity upon myocyte terminal differentiation. Mol Cell Biol (1995) 3.32
Human p300 protein is a coactivator for the transcription factor MyoD. J Biol Chem (1996) 3.05
Depletion of L-3,5,3'-triiodothyronine and L-thyroxine in euthyroid calf serum for use in cell culture studies of the action of thyroid hormone. Endocrinology (1979) 3.04
Regulation of the MEF2 family of transcription factors by p38. Mol Cell Biol (1999) 3.02
Thyroid hormone receptor alpha isoforms generated by alternative splicing differentially activate myosin HC gene transcription. Nature (1988) 2.56
Targeting of p38 mitogen-activated protein kinases to MEF2 transcription factors. Mol Cell Biol (1999) 2.36
Versatile molecular glue. Transcriptional control. Curr Biol (1996) 1.85
p300 requires its histone acetyltransferase activity and SRC-1 interaction domain to facilitate thyroid hormone receptor activation in chromatin. Mol Cell Biol (2000) 1.66
Myocyte-specific enhancer factor 2 and thyroid hormone receptor associate and synergistically activate the alpha-cardiac myosin heavy-chain gene. Mol Cell Biol (1997) 1.21
Thyroid hormone-independent interaction between the thyroid hormone receptor beta2 amino terminus and coactivators. J Biol Chem (2000) 1.10
Interaction between the pRb2/p130 C-terminal domain and the N-terminal portion of cyclin D3. J Cell Biochem (1999) 0.80
2013 ESH/ESC guidelines for the management of arterial hypertension: the Task Force for the Management of Arterial Hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC). Eur Heart J (2013) 12.73
MicroRNA-133 controls cardiac hypertrophy. Nat Med (2007) 11.68
Adult c-kit(pos) cardiac stem cells are necessary and sufficient for functional cardiac regeneration and repair. Cell (2013) 4.99
Effects of Proprotein Convertase Subtilisin/Kexin Type 9 Antibodies in Adults With Hypercholesterolemia: A Systematic Review and Meta-analysis. Ann Intern Med (2015) 4.62
ErbB2 is essential in the prevention of dilated cardiomyopathy. Nat Med (2002) 3.36
Antihypertensive treatment and development of heart failure in hypertension: a Bayesian network meta-analysis of studies in patients with hypertension and high cardiovascular risk. Arch Intern Med (2010) 3.15
An oscillatory switch in mTOR kinase activity sets regulatory T cell responsiveness. Immunity (2010) 2.71
MicroRNAs and cardiac pathology. Nat Rev Cardiol (2009) 2.50
High glucose causes upregulation of cyclooxygenase-2 and alters prostanoid profile in human endothelial cells: role of protein kinase C and reactive oxygen species. Circulation (2003) 2.44
Emerging role of microRNAs in cardiovascular biology. Circ Res (2007) 2.41
MicroRNA-133a protects against myocardial fibrosis and modulates electrical repolarization without affecting hypertrophy in pressure-overloaded adult hearts. Circ Res (2009) 2.40
DNA damage, homology-directed repair, and DNA methylation. PLoS Genet (2007) 2.29
Differential regulation of E2F1 apoptotic target genes in response to DNA damage. Nat Cell Biol (2003) 2.24
Association of the FOXO3A locus with extreme longevity in a southern Italian centenarian study. Rejuvenation Res (2009) 2.24
Anakinra, a recombinant human interleukin-1 receptor antagonist, inhibits apoptosis in experimental acute myocardial infarction. Circulation (2008) 2.23
Growth properties of cardiac stem cells are a novel biomarker of patients' outcome after coronary bypass surgery. Circulation (2013) 2.19
Relation of various plasma growth factor levels in patients with stable angina pectoris and total occlusion of a coronary artery to the degree of coronary collaterals. Am J Cardiol (2005) 2.14
CaMK4 Gene Deletion Induces Hypertension. J Am Heart Assoc (2012) 2.14
Routine assessment of on-clopidogrel platelet reactivity and gene polymorphisms in predicting clinical outcome following drug-eluting stent implantation in patients with stable coronary artery disease. JACC Cardiovasc Interv (2013) 2.11
Differential roles of GSK-3β during myocardial ischemia and ischemia/reperfusion. Circ Res (2011) 2.10
Akt mediates the cross-talk between beta-adrenergic and insulin receptors in neonatal cardiomyocytes. Circ Res (2004) 2.08
MTORC1 regulates cardiac function and myocyte survival through 4E-BP1 inhibition in mice. J Clin Invest (2010) 2.04
Deregulation of microRNA-503 contributes to diabetes mellitus-induced impairment of endothelial function and reparative angiogenesis after limb ischemia. Circulation (2011) 1.99
Association of atrial natriuretic peptide and type a natriuretic peptide receptor gene polymorphisms with left ventricular mass in human essential hypertension. J Am Coll Cardiol (2006) 1.98
Reciprocal regulation of microRNA-1 and insulin-like growth factor-1 signal transduction cascade in cardiac and skeletal muscle in physiological and pathological conditions. Circulation (2009) 1.92
Expert consensus document from the European Society of Cardiology on catheter-based renal denervation. Eur Heart J (2013) 1.90
Selective inhibition of protein kinase Cbeta2 prevents acute effects of high glucose on vascular cell adhesion molecule-1 expression in human endothelial cells. Circulation (2004) 1.88
IkappaB kinase epsilon and TANK-binding kinase 1 activate AKT by direct phosphorylation. Proc Natl Acad Sci U S A (2011) 1.87
Gene silencing of the mitochondrial adaptor p66(Shc) suppresses vascular hyperglycemic memory in diabetes. Circ Res (2012) 1.85
Angiotensin type 2 receptor in resistance arteries of type 2 diabetic hypertensive patients. Hypertension (2006) 1.80
MicroRNAs: components of an integrated system controlling cardiac development, physiology, and disease pathogenesis. Cardiovasc Res (2008) 1.75
MicroRNA-199b targets the nuclear kinase Dyrk1a in an auto-amplification loop promoting calcineurin/NFAT signalling. Nat Cell Biol (2010) 1.74
Translating cardioprotection for patient benefit: position paper from the Working Group of Cellular Biology of the Heart of the European Society of Cardiology. Cardiovasc Res (2013) 1.72
Deletion of p66shc gene protects against age-related endothelial dysfunction. Circulation (2004) 1.69
MicroRNA-133 controls vascular smooth muscle cell phenotypic switch in vitro and vascular remodeling in vivo. Circ Res (2011) 1.67
MicroRNA control of podosome formation in vascular smooth muscle cells in vivo and in vitro. J Cell Biol (2010) 1.64
Genetic deletion of p66(Shc) adaptor protein prevents hyperglycemia-induced endothelial dysfunction and oxidative stress. Proc Natl Acad Sci U S A (2007) 1.63
Assessment of flow-mediated dilation reproducibility: a nationwide multicenter study. J Hypertens (2012) 1.62
Circulating biomarkers with preventive, diagnostic and prognostic implications in cardiovascular diseases. Int J Cardiol (2011) 1.62
Direct intramyocardial percutaneous delivery of autologous bone marrow in patients with refractory myocardial angina. Am Heart J (2006) 1.59
Mammalian target of rapamycin signaling in cardiac physiology and disease. Circ Res (2014) 1.59
Rheb is a critical regulator of autophagy during myocardial ischemia: pathophysiological implications in obesity and metabolic syndrome. Circulation (2012) 1.56
MiR-143/145 deficiency attenuates the progression of atherosclerosis in Ldlr-/-mice. Thromb Haemost (2014) 1.53
Genetic polymorphism of the renin-angiotensin-aldosterone system and arterial hypertension in the Italian population: the GENIPER Project. J Hypertens (2003) 1.52
New evidence of the presence of endometriosis in the human fetus. Reprod Biomed Online (2010) 1.52
Nephrotoxicity of low-osmolality versus iso-osmolality contrast agents: impact of N-acetylcysteine. Kidney Int (2005) 1.52
Cardiovascular health in migrants: current status and issues for prevention. A collaborative multidisciplinary task force report. J Cardiovasc Med (Hagerstown) (2014) 1.50
Aqueous humor levels of vascular endothelial growth factor before and after intravitreal bevacizumab in type 3 versus type 1 and 2 neovascularization. A prospective, case-control study. Am J Ophthalmol (2011) 1.49
Do diabetes, metabolic syndrome or their association equally affect biventricular function? A tissue Doppler study. Hypertens Res (2012) 1.49
Angiotensin receptor blockers: therapeutic targets and cardiovascular protection. Blood Press (2005) 1.49
Activation or inactivation of cardiac Akt/mTOR signaling diverges physiological from pathological hypertrophy. J Cell Physiol (2008) 1.48
SOCS1 gene transfer accelerates the transition to heart failure through the inhibition of the gp130/JAK/STAT pathway. Cardiovasc Res (2012) 1.48
Left bundle-branch block--pathophysiology, prognosis, and clinical management. Clin Cardiol (2007) 1.48
Nitric-oxide-mediated relaxations in salt-induced hypertension: effect of chronic beta1 -selective receptor blockade. J Hypertens (2002) 1.47
Mechanism of enhanced cardiac function in mice with hypertrophy induced by overexpressed Akt. J Biol Chem (2003) 1.47
Functional cross-talk between angiotensin II and epidermal growth factor receptors in NIH3T3 fibroblasts. J Hypertens (2002) 1.46
Delayed neutrophil apoptosis in patients with unstable angina: relation to C-reactive protein and recurrence of instability. Eur Heart J (2009) 1.46
Hypertension guidelines: criteria that might make them more clinically useful. Am J Hypertens (2002) 1.45
Natriuretic peptides: an update on bioactivity, potential therapeutic use, and implication in cardiovascular diseases. Am J Hypertens (2008) 1.44
TET2 and CSMD1 genes affect SBP response to hydrochlorothiazide in never-treated essential hypertensives. J Hypertens (2015) 1.43
Rethinking targets of blood pressure and guidelines for hypertension clinical management. Nephrol Dial Transplant (2010) 1.42
Altered regulation of endothelin A receptor subtype in the cerebral arterioles in response to a Japanese-style diet, in stroke-prone hypertensive rats. J Hypertens (2003) 1.41
Cardiovascular side effects of cancer therapies: a position statement from the Heart Failure Association of the European Society of Cardiology. Eur J Heart Fail (2011) 1.40
The management of the type 2 diabetic patient with hypertension - too late and too little: suggested improvements. Blood Press (2008) 1.40
Lack of protective role of HDL-C in patients with coronary artery disease undergoing elective coronary artery bypass grafting. Eur Heart J (2013) 1.40
Olmesartan-based therapies: an effective way to improve blood pressure control and cardiovascular protection. J Hypertens (2013) 1.39
[Hypertensive heart disease: diagnostic and therapeutic guidelines]. G Ital Cardiol (Rome) (2008) 1.39
Antihypertensive efficacy of olmesartan medoxomil and ramipril in elderly patients with mild to moderate hypertension grouped according to renal function status : a retrospective analysis. High Blood Press Cardiovasc Prev (2013) 1.39
Physiological myocardial hypertrophy: how and why? Front Biosci (2008) 1.35
The Pl(A1/A2) polymorphism of glycoprotein IIIa and cerebrovascular events in hypertension: increased risk of ischemic stroke in high-risk patients. J Hypertens (2007) 1.35
MicroRNA and cardiac pathologies. Physiol Genomics (2008) 1.32
Arterial stiffness as an independent predictor of longitudinal changes in cognitive function in the older individual. J Hypertens (2007) 1.32
Interval training normalizes cardiomyocyte function, diastolic Ca2+ control, and SR Ca2+ release synchronicity in a mouse model of diabetic cardiomyopathy. Circ Res (2009) 1.29
Akt regulates L-type Ca2+ channel activity by modulating Cavalpha1 protein stability. J Cell Biol (2009) 1.28
Transplantation of low dose CD34+KDR+ cells promotes vascular and muscular regeneration in ischemic limbs. FASEB J (2004) 1.27
Inhibition of class I histone deacetylase with an apicidin derivative prevents cardiac hypertrophy and failure. Cardiovasc Res (2008) 1.26
Atrial natriuretic peptide gene polymorphisms and risk of ischemic stroke in humans. Stroke (2004) 1.22
Arterial stiffness is an independent risk factor for cognitive impairment in the elderly: a pilot study. J Hypertens (2005) 1.22
Abdominal obesity is associated with microalbuminuria and an elevated cardiovascular risk profile in patients with hypertension. Vasc Health Risk Manag (2009) 1.22
Distribution of the serine protease HtrA1 in normal human tissues. J Histochem Cytochem (2003) 1.21
Insulin-like growth factor-1 as a vascular protective factor. Circulation (2004) 1.21
Angiotensin-converting enzyme inhibitors, angiotensin II receptor blockers and diabetes: a meta-analysis of placebo-controlled clinical trials. Am J Hypertens (2011) 1.21
Frequent loss of hMLH1 by promoter hypermethylation leads to microsatellite instability in adenomatous polyps of patients with a single first-degree member affected by colon cancer. Cancer Res (2003) 1.20
Circulating microRNAs and aerobic fitness--the HUNT-Study. PLoS One (2013) 1.20
MicroRNAs in cardiovascular biology and heart disease. Circ Cardiovasc Genet (2009) 1.19
Regulation of cell size and contractile function by AKT in cardiomyocytes. Ann N Y Acad Sci (2004) 1.19
Electron microscopy characterization of cardiomyocyte apoptosis in ischemic heart disease. Int J Cardiol (2005) 1.19
A global perspective on blood pressure treatment and control in a referred cohort of hypertensive patients. J Clin Hypertens (Greenwich) (2010) 1.18
Association study on long-living individuals from Southern Italy identifies rs10491334 in the CAMKIV gene that regulates survival proteins. Rejuvenation Res (2011) 1.17
Induced pluripotent stem cell-derived cardiomyocytes in studies of inherited arrhythmias. J Clin Invest (2013) 1.17
Akt/protein kinase B and endothelial nitric oxide synthase mediate muscular neovascularization induced by tissue kallikrein gene transfer. Circulation (2004) 1.15
AKT participates in endothelial dysfunction in hypertension. Circulation (2004) 1.15
Cyclin T: three forms for different roles in physiological and pathological functions. J Cell Physiol (2003) 1.15
Myocardial sarcoplasmic reticulum Ca2+ ATPase function is increased by aerobic interval training. Eur J Cardiovasc Prev Rehabil (2008) 1.13